Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB has announced that the United States Patent and Trademark Office has issued a notification for a US patent covering the combination therapy of resomelagon (AP1189) with methotrexate for treating rheumatoid arthritis. The patent, which will now expire in June 2042 due to a Patent Term Adjustment, strengthens SynAct’s intellectual property rights and enhances market exclusivity, potentially increasing the value of resomelagon as it reaches peak sales.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company develops a broad portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases by inducing anti-inflammatory activity to help patients achieve immune balance.
YTD Price Performance: 109.93%
Average Trading Volume: 188,003
Current Market Cap: SEK922.3M
For an in-depth examination of SYNACT stock, go to TipRanks’ Stock Analysis page.